Core Laboratories (NYSE:CLB) Expected to Announce Quarterly Sales of $173.57 Million

Analysts expect that Core Laboratories (NYSE:CLB) will report $173.57 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Core Laboratories’ earnings, with the highest sales estimate coming in at $174.00 million and the lowest estimate coming in at $173.10 million. Core Laboratories reported sales of $175.48 million in the same quarter last year, which indicates a negative year over year growth rate of 1.1%. The company is scheduled to announce its next earnings report on Wednesday, July 24th.

On average, analysts expect that Core Laboratories will report full-year sales of $715.49 million for the current financial year, with estimates ranging from $707.63 million to $724.70 million. For the next year, analysts expect that the firm will post sales of $786.23 million, with estimates ranging from $775.04 million to $797.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Core Laboratories.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, April 24th. The oil and gas company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.01. Core Laboratories had a net margin of 13.79% and a return on equity of 57.13%. The firm had revenue of $169.19 million for the quarter, compared to the consensus estimate of $166.79 million. During the same period in the prior year, the firm earned $0.57 EPS. The firm’s revenue for the quarter was down .5% on a year-over-year basis.

A number of equities research analysts have commented on the stock. Stifel Nicolaus set a $75.00 price objective on shares of Core Laboratories and gave the company a “buy” rating in a research report on Friday, April 26th. Tudor Pickering raised shares of Core Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $86.45.

CLB traded down $1.61 during trading hours on Friday, hitting $47.99. 622,250 shares of the company’s stock were exchanged, compared to its average volume of 616,688. Core Laboratories has a 12-month low of $46.32 and a 12-month high of $126.70. The company has a market cap of $2.20 billion, a P/E ratio of 21.05, a PEG ratio of 1.94 and a beta of 1.95. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 1.92.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, May 21st. Shareholders of record on Friday, April 26th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 4.58%. The ex-dividend date of this dividend was Thursday, April 25th. Core Laboratories’s dividend payout ratio is presently 96.49%.

Several large investors have recently made changes to their positions in the business. Bremer Bank National Association purchased a new position in shares of Core Laboratories in the 1st quarter valued at $30,000. Marshall Wace LLP purchased a new position in shares of Core Laboratories in the 1st quarter valued at $30,000. Bremer Trust National Association purchased a new position in shares of Core Laboratories in the 4th quarter valued at $43,000. Rockefeller Capital Management L.P. purchased a new position in shares of Core Laboratories in the 1st quarter valued at $43,000. Finally, Cresset Asset Management LLC purchased a new position in shares of Core Laboratories in the 1st quarter valued at $49,000.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Featured Article: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.